When was MabPlex founded?

MabPlex was founded in 2013 and raised its 1st funding round 6 years after it was founded.

Where is MabPlex located?

MabPlex is headquartered in Yantai, China.

How many employees does MabPlex have?

As of Apr 30, 2026, the latest employee count at MabPlex is 10.

Is MabPlex a funded company?

MabPlex is a funded company, having raised a total of $130M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jan 21, 2019.

When was the latest funding round of MabPlex?

MabPlex's latest funding was a $***** Series B round on Jun 08, 2020, with participation from 8 investors. Its primary sector is Biopharma Outsourcing. In China, the Biopharma Outsourcing sector has seen $50.6M in funding in 2026 to date.

Where does MabPlex rank among its competitors?

MabPlex ranks 12th amongst 44 active competitors, of which 4 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Kashiv BioSciences, which secured $72.3M in Dec, 2025.

Who are the top competitors of MabPlex?

MabPlex's top competitors include 64x Bio, Bionova Scientific and Just Biotherapeutics. Among them, Kashiv BioSciences secured the most recent funding round in December, 2025.

MabPlex - 2026 Company Profile, Funding & Competitors

MabPlex is a series B company based in Yantai (China), founded in 2013. It operates as a CDMO offering biologics development and manufacturing services. MabPlex has raised $130M in funding from investors like Shenzhen Capital Group, Detong Capital and SDIC Venture Capital Management. The company has 44 active competitors, including 4 funded and 15 that have exited. Its top competitors include companies like 64x Bio, Bionova Scientific and Just Biotherapeutics.

Company Details

MabPlex offers biologics development and manufacturing services. They are capable of offering services for the development and GMP manufacturing of ADC(Antibody Drug Conjugates), mammalian cell-line based APIs and biologics. They also offer GMP Cell banking, MAb generation, protein characterization services, formulation, lyophilization fill/finish for ADCs, fusion proteins MAbs and final product packaging. Quality Assurance & Control and regulatory services (which they claim to be compliant with FDA, EMA, and CFDA) are also offered by MabPlex.

Website: mabplexinc.com
Social
Email ID: *****@mabplexinc.com

Key Metrics

Founded Year

2013

Location

Yantai, China

Stage

Series B

Total Funding

$130M in 2 rounds

Latest Funding Round

Series B, Jun 08, 2020, $*****

Investors

Shenzhen Capital Group & 10 more

Ranked

12^th among 44 active competitors

Employee Count

10 as on Apr 30, 2026

Similar Companies

64x Bio & 51 more

View MabPlex's full profile

MabPlex has raised a total funding of $130M over 2 rounds. Its first funding round was on Jan 21, 2019. Its latest funding round was a Series B round on Jun 08, 2020 for $*****. 8 investors participated in its latest round. MabPlex has 11 institutional investors.

Here is the list of recent funding rounds of MabPlex:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 08, 2020	1167047	Series B	8170764	8987904	7687095	5376173
Jan 21, 2019	8180850	Series A	6988759	1842889	Shenzhen Capital Group & 1 more	9239919

Access funding benchmarks and valuations. Sign up today!

View details of MabPlex's funding rounds and investors

MabPlex's employee count trend

MabPlex has 10 employees as of Apr 26. Here is MabPlex's employee count trend over the years:

Uncover MabPlex's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of MabPlex include 64x Bio, Bionova Scientific and Just Biotherapeutics. Here is the list of Top 10 competitors of MabPlex, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	64x Bio 2017, San Francisco (United States), Series A	Developer of cell lines and production technologies for advanced therapies	$59.6M	Y Combinator, Fifty Years & 13 others	61/100
2nd	Bionova Scientific 2013, Fremont (United States), Acquired	Contract Research and Development company developing mammalian cell culture biologics	$22M	CRG, Great Point Partners	55/100
3rd	Just Biotherapeutics 2014, Seattle (United States), Acquired	Designing technologies to accelerate biotherapeutic development and to reduce manufacturing costs	$124M	Lilly Asia Ventures, Temasek & 10 others	53/100
4th	Avid Bioservices 2002, Orange (United States), Acquired	CDMO focused on drug substance development, analytical, and quality & regulatory compliance services	-	Ranger Investments, Ampersand Capital & 3 others	51/100
5th	JHL Biotech 2012, Hsinchu (Taiwan), Series D	CDMO solutions to companies developing and commercializing affordable biologics	$187M	Sequoia Capital, Sanofi & 11 others	51/100
6th	Rentschler Biopharma 1927, Laupheim (Germany), Funding Raised	Full-service CDMO for biopharmaceuticals	-	-	50/100
7th	Excellgene 2001, Monthey (Switzerland), Acquired	Provider of service covering value chain from DNA vector to purified protein	-	Kulczyk Investments, BioArk	48/100
8th	Kashiv BioSciences 2010, Piscataway (United States), Acquired	Developer of biosimilar medicines	-	GoldenTree	47/100
9th	AGC Biologics 2018, Bothell (United States), Unfunded	CDMO focused on development of mammalian and microbial-based therapeutic proteins	-	European Equity Partners	47/100
10th	ProBioGen AG 1994, Berlin (Germany), Acquired	Contract development and manufacturing organization focussed on therapeutic proteins/antibodies, viral vaccines and biosimilars	-	SudBG, SHS & 2 others	45/100
12th	MabPlex 2013, Yantai (China), Series B	CDMO offering biologics development and manufacturing services	$130M	Orbimed, China Merchants Securities & 9 others	42/100